Four hepatitis C drugs have demonstrated promise as boosters to increase the efficacy of remdesivir against SARS-CoV-2 by as much as tenfold.
List view / Grid view
Recent years have seen an increase in the development of biomaterial and nanoparticle-based vaccine formulations. Sushma Kumari, Sonal Asthana and Kaushik Chatterjee from the Department of Materials Engineering at the Indian Institute of Science discuss why these materials have such high potential in the fight against infectious diseases.
The length of time between the administration of a COVID-19 vaccine and evidence of a robust immune response to Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) means that treatments are still required. In this article, Sheraz Gul and Alp Tegin Sahin explore the various therapeutic targets that have been identified…
Researchers have found that spermidine can ramp up autophagy and boost T-cell function, potentially increasing the protective effects of vaccines in older adults.
Scientists reveal that coronaviruses de-activate lysosomes before using them to exit infected cells and spread through the body.
The 2020 Nobel Prize in Physiology or Medicine has been bestowed upon researchers who helped identify the hepatitis C virus in the 1970s.
In human cells, a drug candidate called PF-00835231 has demonstrated success at blocking the reproduction of SARS-CoV-2.
Scientists reveal eight new molecules, five of which are already US FDA-approved, that can block the polymerase reaction SARS-CoV-2 uses to replicate its genome.
Researchers have demonstrated that blocking CD47-mediated signalling in mice can enhance the speed of pathogen clearance, presenting a new potential form of immunotherapy.
A group of researchers has created a free library of 14,000 known macrolactones for other scientists to use in drug development.
A new discovery on how the immune system responds to malaria infection could lead to better treatments for hepatitis C, HIV and lupus.
Researchers have identified differences in gene transcription within key immune cells that may distinguish those individuals infected with HCV...
Daiichi Sankyo has entered into a new joint research agreement with the Drugs for Neglected Diseases initiative (DNDi) with regard to a new research program, the Hit-to-Lead Project, with the aim of developing drug treatments for two neglected tropical diseases, leishmaniasis and Chagas disease.
17 May 2016 | By Katie Sadler
Virologists have discovered that an antiviral drug against hepatitis C has helped slow down the development of Zika virus in Mice.